Objective To analyze the efficacy and safety of sodium-dependent glucose transporters 2(SGLT-2)inhibi-tor dapagliflozin in the treatment of early diabetic nephropathy.Methods 100 early diabetic nephropathy patients ad-mitted to Beijing Sixth Hospital from March 2022 to December 2023 were selected as the study objects.According to the method of random number table,they were divided into the study group and the control group,with 50 cases in each group.All patients were given routine treatment,dapagliflozin was added in the study group and metformin was added in the control group.Blood glucose levels,renal function and adverse reactions were compared between two groups.Results The fasting blood glucose in the study group was(5.16±0.77)mmol/L,2 h postprandial blood glucose was(7.11±1.38)mmol/L,glycosylated hemoglobin A1c was(5.05±0.73)%,which were lower than those of the control group,the differences were statistically significant(t=4.592,5.020,5.093,all P<0.05).Urine albumin/creatine ratio and glomerular filtration rate in the study group after treatment were better than those of the control group,the differ-ences were statistically significant(both P<0.05).The incidence of adverse reactions in study group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion The use of SGLT-2 inhibitor dapagliflozin in the treatment of early diabetic nephropathy has a significant effect,which can reduce blood glucose level,improve the renal function,and reduce the incidence of adverse reactions.
NETL
NSTL
万方数据
